This product is a recombinant mouse antibody Fab fragment that recognizes VEGFA. G6-31 recognises a VEGF epitope which is conserved between human and mouse VEGF and overlaps with the receptor binding surface.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-011 | Anti-Human VEGF Recombinant Antibody (Bevacizumab) | FC, IP, ELISA, Neut, FuncS, IF, ICC | IgG1 - kappa |
TAB-012-F(E) | Anti-Human VEGF Recombinant Antibody Fab Fragment (TAB-012-F(E)) | IP, IF, FuncS, FC, Neut, ELISA, IHC | Fab - G1 - kappa |
TAB-307CQ | Human Anti-VEGFA Recombinant Antibody (TAB-307CQ) | Inhib | Human IgG |
TAB-307CQ-F(E) | Human Anti-VEGFA Recombinant Antibody; Fab Fragment (TAB-307CQ-F(E)) | ELISA, Neut | Humanized Fab |
TAB-009ML | Anti-Human VEGFA Recombinant Antibody scFv Fragment (TAB-009ML) | ELISA, IHC, FC, IP, IF, Inhib | scFv, κ |
There are currently no Customer reviews or questions for HPAB-0330CQ-F(E). Click the button above to contact us or submit your feedback about this product.
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# HPAB-0330CQ-F(E), RRID: AB_3111387)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.